Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals Top-Line Results of Second Cohort (50mg) of Part A of Phase 2 ACHIEVE Trial  (Replay)
    Thursday, November 16, 2017 8:00 am EST
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results
Reports multiple recent developments and milestones Plans to report top-line results from the second monotherapy dosing cohort of the ACHIEVE global Phase 2 clinical trial of SB 9200 in chronic HBV in 4Q 2017 Successful $40 million equity financing expected to fund company through end of 2019
Toggle Summary Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
HOPKINTON, Mass. , July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial
Toggle Summary Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock
HOPKINTON, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today the pricing of its
Toggle Summary Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOPKINTON, Mass. , June 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that it intends to
Toggle Summary Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
SB 11285 Shows Potent and Durable, Immune-Mediated Anti-Tumor Activity in Both Lymphoma and Colon Cancer Animal Models HOPKINTON, Mass. , June 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was
Toggle Summary Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
SB 9200 Shows Favorable Safety Profile and Significant Antiviral Activity  Against HBV DNA and HBsAg with Initial Low Dose Monotherapy of 25mg Conference Call Scheduled for Tomorrow, May 24 th at 8:00 a.m. ET HOPKINTON, Mass. , May 23, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.
Toggle Summary Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial
HOPKINTON, Mass. , May 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that the company’s management team
Toggle Summary Spring Bank Pharmaceuticals Announces the Data Safety Monitoring Board Approves Dose Escalation of SB 9200 for the Second Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
Begins Screening Patients for Second Cohort of the Global Phase 2a ACHIEVE Trial HOPKINTON, Mass. , May 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,
Toggle Summary Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston
HOPKINTON, Mass. , May 01, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals (NASDAQ:SBPH) today announced that Martin Driscoll , president and chief executive officer of Spring Bank Pharmaceuticals , will present at the East Coast IDEAS Investor Conference on May 18, 2017 at the Boston Park
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results
Completes monotherapy dosing in first cohort of the ACHIEVE global Phase 2a clinical trial of SB 9200 in chronic HBV patients HOPKINTON, Mass. , April 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel